drugset
drugset / Trial / NCT01840501

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

NCT01840501 ↗

Phase 1 Completed 108 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the body does to the medication), potential immunogenicity (ability to induce an immune response), and pharmacodynamics (what the drug does to the body) after administration of JNJ-42721458 in healthy adult male participants.

Timeline

Start
2013-04
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-42721458 Unknown 0.1 mg Subcutaneous
Subject JNJ-42721458 Unknown 0.3 mg Subcutaneous
Subject JNJ-42721458 Unknown 1 mg Subcutaneous
Subject JNJ-42721458 Unknown 2.5 mg Subcutaneous
Subject JNJ-42721458 Unknown 5 mg Subcutaneous
Subject JNJ-42721458 Unknown 10 mg Subcutaneous
Subject JNJ-42721458 Unknown 20 mg Subcutaneous

Indications

No indication recorded.